Symptomatic Necrosis With Antibody-Drug Conjugates and Concurrent Stereotactic Radiotherapy for Brain Metastases

Emily S Lebow; Luke R G Pike; Andrew D Seidman; Nelson Moss; Kathryn Beal; Yao Yu

doi:10.1001/jamaoncol.2023.4492

Symptomatic Necrosis With Antibody-Drug Conjugates and Concurrent Stereotactic Radiotherapy for Brain Metastases

JAMA Oncol. 2023 Dec 1;9(12):1729-1733. doi: 10.1001/jamaoncol.2023.4492.

Authors

Emily S Lebow^{1

2}, Luke R G Pike¹, Andrew D Seidman³, Nelson Moss⁴, Kathryn Beal⁵, Yao Yu¹

Affiliations

¹ Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
² Department of Radiation Oncology, University of Pennsylvania, Philadelphia.
³ Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
⁴ Department of Neurosurgery, Memorial Sloan Kettering Cancer Center, News York, New York.
⁵ Department of Radiation Oncology, Weill Cornell Medical Center, New York, New York.

PMID: 37883079
PMCID: PMC10603573 (available on 2024-10-26)
DOI: 10.1001/jamaoncol.2023.4492

No abstract available

Plain language summary

This cohort study investigates whether brain metastases that manifest after stereotactic radiotherapy with concurrent antibody-drug conjugates are associated with an increased risk of symptomatic radiation necrosis.

MeSH terms

Brain / pathology
Brain Neoplasms* / secondary
Humans
Immunoconjugates*
Necrosis / pathology
Radiosurgery* / adverse effects
Retrospective Studies

Substances

Immunoconjugates

Grants and funding

P30 CA008748/CA/NCI NIH HHS/United States